{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:02:44Z","timestamp":1767916964458,"version":"3.49.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Research Grant from the University of Florence","award":["RICATEN2023"],"award-info":[{"award-number":["RICATEN2023"]}]},{"name":"European Union \u2013 Next Generation EU. National Recovery and Resilience Plan","award":["Mission 4, Component 2 \u2013 Investment 1.4 \u2013 CUP B13C22001010001"],"award-info":[{"award-number":["Mission 4, Component 2 \u2013 Investment 1.4 \u2013 CUP B13C22001010001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-92674-6","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T02:11:01Z","timestamp":1741399861000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of reduced extracellular sodium on proliferation and invasive activity of renal cell carcinoma cell lines"],"prefix":"10.1038","volume":"15","author":[{"given":"Laura","family":"Naldi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Elena","family":"Melica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Polvani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitri","family":"Papini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida","family":"Landini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6417-434X","authenticated-orcid":false,"given":"Alessandro","family":"Peri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giandomenico","family":"Roviello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"key":"92674_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"92674_CR2","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMOA1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1116\u20131127. https:\/\/doi.org\/10.1056\/NEJMOA1816714 (2019).","journal-title":"N. Engl. J. Med."},{"key":"92674_CR3","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/nejmoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer, R. et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N. Engl. J. Med. 384, 1289\u20131300. https:\/\/doi.org\/10.1056\/nejmoa2035716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"92674_CR4","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/nejmoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri, T. K. et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 384, 829\u2013841. https:\/\/doi.org\/10.1056\/nejmoa2026982 (2021).","journal-title":"N. Engl. J. Med."},{"key":"92674_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/NU15020395","author":"A Bernal","year":"2023","unstructured":"Bernal, A., Zafra, M. A., Sim\u00f3n, M. J. & Mah\u00eda, J. Sodium homeostasis, a balance necessary for life. Nutrients https:\/\/doi.org\/10.3390\/NU15020395 (2023).","journal-title":"Nutrients"},{"key":"92674_CR6","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1056\/NEJM200005253422107","volume":"342","author":"HJ Adrogu\u00e9","year":"2000","unstructured":"Adrogu\u00e9, H. J. & Madias, N. E. Hyponatremia. N. Engl. J. Med. 342, 1581\u20131589. https:\/\/doi.org\/10.1056\/NEJM200005253422107 (2000).","journal-title":"N. Engl. J. Med."},{"key":"92674_CR7","doi-asserted-by":"publisher","first-page":"R78","DOI":"10.1530\/EO-22-0056","volume":"2","author":"DM Donald","year":"2022","unstructured":"Donald, D. M., Sherlock, M. & Thompson, C. J. Hyponatraemia and the syndrome of inappropriate antidiuresis (SIAD) in cancer. Endocr. Oncol. (Bristol, England) 2, R78\u2013R89. https:\/\/doi.org\/10.1530\/EO-22-0056 (2022).","journal-title":"Endocr. Oncol. (Bristol, England)"},{"key":"92674_CR8","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1158\/1078-0432.CCR-07-1721","volume":"14","author":"NS Vasudev","year":"2008","unstructured":"Vasudev, N. S. et al. Prognostic factors in renal cell carcinoma: Association of preoperative sodium concentration with survival. Clin. Cancer Res. 14, 1775\u20131781. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-1721 (2008).","journal-title":"Clin. Cancer Res."},{"key":"92674_CR9","doi-asserted-by":"publisher","unstructured":"Huo, T.-I., et al. The MELD-Na is an independent short-and long-term prognostic predictor for hepatocellular carcinoma: A prospective survey. https:\/\/doi.org\/10.1016\/j.dld.2008.01.015 (2008).","DOI":"10.1016\/j.dld.2008.01.015"},{"key":"92674_CR10","doi-asserted-by":"publisher","first-page":"651","DOI":"10.21037\/tlcr-20-877","volume":"10","author":"B Sandfeld-Paulsen","year":"2021","unstructured":"Sandfeld-Paulsen, B., Aggerholm-Pedersen, N. & Winther-Larsen, A. Hyponatremia as a prognostic factor in non-small cell lung cancer: A systematic review and meta-analysis. Transl. Lung Cancer Res. 10, 651\u2013661 (2021).","journal-title":"Transl. Lung Cancer Res."},{"key":"92674_CR11","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/SJ.BJC.6605563","volume":"102","author":"AN Jeppesen","year":"2010","unstructured":"Jeppesen, A. N., Jensen, H. K., Donskov, F., Marcussen, N. & Von Der Maase, H. Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma. Br. J. Cancer 102, 867\u2013872. https:\/\/doi.org\/10.1038\/SJ.BJC.6605563 (2010).","journal-title":"Br. J. Cancer"},{"key":"92674_CR12","doi-asserted-by":"publisher","first-page":"e0124105","DOI":"10.1371\/journal.pone.0124105","volume":"10","author":"G Corona","year":"2015","unstructured":"Corona, G. et al. Hyponatremia improvement is associated with a reduced risk of mortality: Evidence from a meta-analysis. PLoS One 10, e0124105. https:\/\/doi.org\/10.1371\/journal.pone.0124105 (2015).","journal-title":"PLoS One"},{"key":"92674_CR13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12885-015-1156-6","volume":"15","author":"K Balachandran","year":"2015","unstructured":"Balachandran, K., Okines, A., Gunapala, R., Morganstein, D. & Popat, S. Resolution of severe hyponatraemia is associated with improved survival in patients with cancer. BMC Cancer 15, 163. https:\/\/doi.org\/10.1186\/s12885-015-1156-6 (2015).","journal-title":"BMC Cancer"},{"key":"92674_CR14","doi-asserted-by":"publisher","first-page":"26916","DOI":"10.18632\/oncotarget.8309","volume":"7","author":"R Berardi","year":"2016","unstructured":"Berardi, R. et al. Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy. Oncotarget 7, 26916\u201326924. https:\/\/doi.org\/10.18632\/oncotarget.8309 (2016).","journal-title":"Oncotarget"},{"key":"92674_CR15","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.eururo.2013.10.013","volume":"65","author":"FAB Schutz","year":"2014","unstructured":"Schutz, F. A. B. et al. The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium. Eur. Urol. 65, 723\u2013730. https:\/\/doi.org\/10.1016\/j.eururo.2013.10.013 (2014).","journal-title":"Eur. Urol."},{"key":"92674_CR16","doi-asserted-by":"publisher","unstructured":"Bellmunt, J, et al. Platinum priority-kidney cancer the impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium. 731\u2013732. https:\/\/doi.org\/10.1016\/j.eururo.2013.10.013.","DOI":"10.1016\/j.eururo.2013.10.013"},{"key":"92674_CR17","doi-asserted-by":"publisher","first-page":"918413","DOI":"10.3389\/fonc.2022.918413","volume":"12","author":"G Roviello","year":"2022","unstructured":"Roviello, G. et al. Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors. Front. Oncol. 12, 918413. https:\/\/doi.org\/10.3389\/fonc.2022.918413 (2022).","journal-title":"Front. Oncol."},{"key":"92674_CR18","doi-asserted-by":"publisher","first-page":"2345185","DOI":"10.1001\/jamanetworkopen.2023.45185","volume":"6","author":"M Catalano","year":"2023","unstructured":"Catalano, M. et al. Sodium levels and outcomes in patients with metastatic renal cell carcinoma receiving nivolumab + supplemental content. JAMA Netw. Open 6, 2345185. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.45185 (2023).","journal-title":"JAMA Netw. Open"},{"key":"92674_CR19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1089\/BIOE.2019.0035","volume":"2","author":"MBA Djamgoz","year":"2020","unstructured":"Djamgoz, M. B. A. Hyponatremia and cancer progression: Possible association with sodium-transporting proteins. Bioelectricity 2, 14. https:\/\/doi.org\/10.1089\/BIOE.2019.0035 (2020).","journal-title":"Bioelectricity"},{"key":"92674_CR20","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/S41577-018-0113-4","volume":"19","author":"DN M\u00fcller","year":"2019","unstructured":"M\u00fcller, D. N., Wilck, N., Haase, S., Kleinewietfeld, M. & Linker, R. A. Sodium in the microenvironment regulates immune responses and tissue homeostasis. Nat. Rev. Immunol. 19, 243\u2013254. https:\/\/doi.org\/10.1038\/S41577-018-0113-4 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"92674_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2019.00124\/BIBTEX","volume":"9","author":"W Mao","year":"2019","unstructured":"Mao, W., Zhang, J., K\u00f6rner, H., Jiang, Y. & Ying, S. The emerging role of voltage-gated sodium channels in tumor biology. Front. Oncol. 9, 427250. https:\/\/doi.org\/10.3389\/FONC.2019.00124\/BIBTEX (2019).","journal-title":"Front. Oncol."},{"key":"92674_CR22","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s12020-019-02135-0","volume":"67","author":"G Marroncini","year":"2020","unstructured":"Marroncini, G. et al. Effects of low extracellular sodium on proliferation and invasive activity of cancer cells in vitro. Endocrine 67, 473\u2013484. https:\/\/doi.org\/10.1007\/s12020-019-02135-0 (2020).","journal-title":"Endocrine"},{"key":"92674_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2021.111419","volume":"537","author":"G Marroncini","year":"2021","unstructured":"Marroncini, G. et al. Low sodium and tolvaptan have opposite effects in human small cell lung cancer cells. Mol. Cell. Endocrinol. 537, 111419. https:\/\/doi.org\/10.1016\/j.mce.2021.111419 (2021).","journal-title":"Mol. Cell. Endocrinol."},{"key":"92674_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242316680","author":"G Marroncini","year":"2023","unstructured":"Marroncini, G. et al. Hyponatremia promotes cancer growth in a murine xenograft model of neuroblastoma. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms242316680 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"92674_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084377","author":"L Naldi","year":"2024","unstructured":"Naldi, L. et al. Effects of reduced extracellular sodium concentrations on cisplatin treatment in human tumor cells: The role of autophagy. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms25084377 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"92674_CR26","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.semcancer.2019.06.002","volume":"59","author":"S Revathidevi","year":"2019","unstructured":"Revathidevi, S. & Munirajan, A. K. Akt in cancer: Mediator and more. Semin. Cancer Biol. 59, 80\u201391. https:\/\/doi.org\/10.1016\/j.semcancer.2019.06.002 (2019).","journal-title":"Semin. Cancer Biol."},{"key":"92674_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semcancer.2021.05.010","volume":"85","author":"R Ullah","year":"2022","unstructured":"Ullah, R., Yin, Q., Snell, A. H. & Wan, L. RAF-MEK-ERK pathway in cancer evolution and treatment. Semin. Cancer Biol. 85, 123\u2013154. https:\/\/doi.org\/10.1016\/j.semcancer.2021.05.010 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"92674_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/cells9122648","author":"FI Montalto","year":"2020","unstructured":"Montalto, F. I. & De Amicis, F. Cyclin D1 in cancer: A molecular connection for cell cycle control, adhesion and invasion in tumor and stroma. Cells https:\/\/doi.org\/10.3390\/cells9122648 (2020).","journal-title":"Cells"},{"key":"92674_CR29","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1093\/aob\/mcq243","volume":"107","author":"W Strzalka","year":"2011","unstructured":"Strzalka, W. & Ziemienowicz, A. Proliferating cell nuclear antigen (PCNA): A key factor in DNA replication and cell cycle regulation. Ann. Bot. 107, 1127\u20131140. https:\/\/doi.org\/10.1093\/aob\/mcq243 (2011).","journal-title":"Ann. Bot."},{"key":"92674_CR30","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.acthis.2016.05.002","volume":"118","author":"M Jur\u00edkov\u00e1","year":"2016","unstructured":"Jur\u00edkov\u00e1, M., Danihel, \u013d, Pol\u00e1k, \u0160 & Varga, I. Ki67, PCNA, and MCM proteins: Markers of proliferation in the diagnosis of breast cancer. Acta Histochem. 118, 544\u2013552. https:\/\/doi.org\/10.1016\/j.acthis.2016.05.002 (2016).","journal-title":"Acta Histochem."},{"key":"92674_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249739","author":"GA Cabral-Pacheco","year":"2020","unstructured":"Cabral-Pacheco, G. A. et al. The roles of matrix metalloproteinases and their inhibitors in human diseases. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms21249739 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"92674_CR32","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/jmi.12025","volume":"251","author":"AJ Ridley","year":"2013","unstructured":"Ridley, A. J. RhoA, RhoB and RhoC have different roles in cancer cell migration. J. Microsc. 251, 242\u2013249. https:\/\/doi.org\/10.1111\/jmi.12025 (2013).","journal-title":"J. Microsc."},{"key":"92674_CR33","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1242\/jcs.133108","volume":"127","author":"J Clucas","year":"2014","unstructured":"Clucas, J. & Valderrama, F. ERM proteins in cancer progression. J. Cell Sci. 127, 267\u2013275. https:\/\/doi.org\/10.1242\/jcs.133108 (2014).","journal-title":"J. Cell Sci."},{"key":"92674_CR34","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ejmech.2013.10.048","volume":"70","author":"R Guan","year":"2013","unstructured":"Guan, R. et al. Advances in the studies of roles of Rho\/Rho-kinase in diseases and the development of its inhibitors. Eur. J. Med. Chem. 70, 613\u2013622. https:\/\/doi.org\/10.1016\/j.ejmech.2013.10.048 (2013).","journal-title":"Eur. J. Med. Chem."},{"key":"92674_CR35","doi-asserted-by":"publisher","first-page":"105796","DOI":"10.1016\/j.biocel.2020.105796","volume":"125","author":"T Zheng","year":"2020","unstructured":"Zheng, T., J\u00e4\u00e4ttel\u00e4, M. & Liu, B. PH gradient reversal fuels cancer progression. Int. J. Biochem. Cell Biol. 125, 105796. https:\/\/doi.org\/10.1016\/j.biocel.2020.105796 (2020).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"92674_CR36","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nrc3110","volume":"11","author":"BA Webb","year":"2011","unstructured":"Webb, B. A., Chimenti, M., Jacobson, M. P. & Barber, D. L. Dysregulated PH: A perfect storm for cancer progression. Nat. Rev. Cancer 11, 671\u2013677 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"92674_CR37","doi-asserted-by":"publisher","first-page":"26991","DOI":"10.1074\/jbc.M311838200","volume":"279","author":"LYW Bourguignon","year":"2004","unstructured":"Bourguignon, L. Y. W., Singleton, P. A., Diedrich, F., Stern, R. & Gilad, E. CD44 interaction with Na+-H+ exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and Cathepsin B activation and breast tumor cell invasion. J. Biol. Chem. 279, 26991\u201327007. https:\/\/doi.org\/10.1074\/jbc.M311838200 (2004).","journal-title":"J. Biol. Chem."},{"key":"92674_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20010039","author":"S-K Chiang","year":"2018","unstructured":"Chiang, S.-K., Chen, S.-E. & Chang, L.-C. A dual role of heme oxygenase-1 in cancer cells. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms20010039 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"92674_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111755","author":"A-A Zimta","year":"2019","unstructured":"Zimta, A.-A. et al. The role of Nrf2 activity in cancer development and progression. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers11111755 (2019).","journal-title":"Cancers (Basel)"},{"key":"92674_CR40","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s12276-024-01180-8","volume":"56","author":"T Bae","year":"2024","unstructured":"Bae, T., Hallis, S. P. & Kwak, M.-K. Hypoxia, oxidative stress, and the interplay of HIFs and NRF2 signaling in cancer. Exp. Mol. Med. 56, 501\u2013514. https:\/\/doi.org\/10.1038\/s12276-024-01180-8 (2024).","journal-title":"Exp. Mol. Med."},{"key":"92674_CR41","doi-asserted-by":"publisher","unstructured":"He, F.; Ru, X.; Wen, T. NRF2, a Transcription Factor for Stress Response and Beyond. Int. J. Mol. Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21134777.","DOI":"10.3390\/ijms21134777"},{"key":"92674_CR42","doi-asserted-by":"publisher","first-page":"1958174","DOI":"10.1155\/2016\/1958174","volume":"2016","author":"AL Furfaro","year":"2016","unstructured":"Furfaro, A. L. et al. The Nrf2\/HO-1 axis in cancer cell growth and chemoresistance. Oxid. Med. Cell. Longev. 2016, 1958174. https:\/\/doi.org\/10.1155\/2016\/1958174 (2016).","journal-title":"Oxid. Med. Cell. Longev."},{"key":"92674_CR43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.vph.2015.09.004","volume":"74","author":"A Loboda","year":"2015","unstructured":"Loboda, A., Jozkowicz, A. & Dulak, J. HO-1\/CO system in tumor growth, angiogenesis and metabolism\u2014targeting HO-1 as an anti-tumor therapy. Vascul. Pharmacol. 74, 11\u201322. https:\/\/doi.org\/10.1016\/j.vph.2015.09.004 (2015).","journal-title":"Vascul. Pharmacol."},{"key":"92674_CR44","doi-asserted-by":"publisher","first-page":"33580","DOI":"10.1074\/jbc.M111.248401","volume":"286","author":"P Banerjee","year":"2011","unstructured":"Banerjee, P. et al. The heme oxygenase-1 protein is overexpressed in human renal cancer cells following activation of the Ras-Raf-ERK pathway and mediates anti-apoptotic signal. J. Biol. Chem. 286, 33580\u201333590. https:\/\/doi.org\/10.1074\/jbc.M111.248401 (2011).","journal-title":"J. Biol. Chem."},{"key":"92674_CR45","doi-asserted-by":"publisher","first-page":"32113","DOI":"10.1074\/jbc.M112.393140","volume":"287","author":"P Banerjee","year":"2012","unstructured":"Banerjee, P. et al. Heme oxygenase-1 promotes survival of renal cancer cells through modulation of apoptosis- and autophagy-regulating molecules. J. Biol. Chem. 287, 32113\u201332123. https:\/\/doi.org\/10.1074\/jbc.M112.393140 (2012).","journal-title":"J. Biol. Chem."},{"key":"92674_CR46","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/35077213","volume":"411","author":"GI Evan","year":"2001","unstructured":"Evan, G. I. & Vousden, K. H. Proliferation, cell cycle and apoptosis in cancer. Nature 411, 342\u2013348. https:\/\/doi.org\/10.1038\/35077213 (2001).","journal-title":"Nature"},{"key":"92674_CR47","doi-asserted-by":"publisher","first-page":"333","DOI":"10.15212\/amm-2022-0022","volume":"1","author":"M Chang","year":"2022","unstructured":"Chang, M., Gao, F., Chen, J., Gnawali, G. & Wang, W. MDM2-BCL-X(L) PROTACs enable degradation of BCL-X(L) and stabilization of P53. Acta Mater. Medica 1, 333\u2013342. https:\/\/doi.org\/10.15212\/amm-2022-0022 (2022).","journal-title":"Acta Mater. Medica"},{"key":"92674_CR48","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1186\/s12885-019-6347-0","volume":"19","author":"Y Yamaguchi","year":"2019","unstructured":"Yamaguchi, Y. et al. Nrf2 gene mutation and single nucleotide polymorphism Rs6721961 of the Nrf2 promoter region in renal cell cancer. BMC Cancer 19, 1137. https:\/\/doi.org\/10.1186\/s12885-019-6347-0 (2019).","journal-title":"BMC Cancer"},{"key":"92674_CR49","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/med.21925","volume":"43","author":"E Crisman","year":"2023","unstructured":"Crisman, E. et al. KEAP1-NRF2 protein\u2013protein interaction inhibitors: Design, pharmacological properties and therapeutic potential. Med. Res. Rev. 43, 237\u2013287. https:\/\/doi.org\/10.1002\/med.21925 (2023).","journal-title":"Med. Res. Rev."},{"key":"92674_CR50","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.addr.2009.02.005","volume":"61","author":"J Fang","year":"2009","unstructured":"Fang, J., Seki, T. & Maeda, H. Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv. Drug Deliv. Rev. 61, 290\u2013302. https:\/\/doi.org\/10.1016\/j.addr.2009.02.005 (2009).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"92674_CR51","first-page":"794","volume":"73","author":"PA Mingote","year":"2020","unstructured":"Mingote, P. A. et al. Expression of Hemeoxygenase-1 and clear cell renal cell carcinoma aggressiveness. Arch. Esp. Urol. 73, 794\u2013802 (2020).","journal-title":"Arch. Esp. Urol."},{"key":"92674_CR52","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1126\/scitranslmed.abg3277","volume":"14","author":"ME Melica","year":"2022","unstructured":"Melica, M. E. et al. Differentiation of crescent-forming kidney progenitor cells into podocytes attenuates severe glomerulonephritis in mice. Sci. Transl. Med. 14, 3277. https:\/\/doi.org\/10.1126\/scitranslmed.abg3277 (2022).","journal-title":"Sci. Transl. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92674-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92674-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92674-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T13:57:19Z","timestamp":1741442239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92674-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["92674"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-92674-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,8]]},"assertion":[{"value":"30 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8067"}}